WR-238605 d3
Modify Date: 2024-01-07 12:46:34
WR-238605 d3 structure
|
Common Name | WR-238605 d3 | ||
|---|---|---|---|---|
| CAS Number | 1133378-83-2 | Molecular Weight | 584.61 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C28H31D3F3N3O7 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of WR-238605 d3Tafenoquine-d3 is a trideuerium-labeled Tafenoquine derivative. Tafenoquine, also known as WR-238605, is an oral active antimalaria drug that is being investigated as a potential treatment for malaria, as well as for malaria prevention. Tafenoquine Shows Activity against Trypanosoma brucei. Tafenoquine targets leishmania respiratory complex III and induces apoptosis. Tafenoquine has a long half-life of approximately 14 days and is generally safe and well tolerated, Malaria remains an important cause of global morbidity and mortality. As antimalarial drug resistance escalates, new safe and effective medications are necessary to prevent and treat malarial infection. |
| Name | WR-238605 d3 |
|---|
| Description | Tafenoquine-d3 is a trideuerium-labeled Tafenoquine derivative. Tafenoquine, also known as WR-238605, is an oral active antimalaria drug that is being investigated as a potential treatment for malaria, as well as for malaria prevention. Tafenoquine Shows Activity against Trypanosoma brucei. Tafenoquine targets leishmania respiratory complex III and induces apoptosis. Tafenoquine has a long half-life of approximately 14 days and is generally safe and well tolerated, Malaria remains an important cause of global morbidity and mortality. As antimalarial drug resistance escalates, new safe and effective medications are necessary to prevent and treat malarial infection. |
|---|
| Molecular Formula | C28H31D3F3N3O7 |
|---|---|
| Molecular Weight | 584.61 |